Adiposis dolorosa, also called Dercum’s disease, is a rare condition in which painful deposits of fatty tissue form beneath the skin, typically in people who are overweight or obese. The pain can be constant, burning, or aching, and it often resists the standard painkillers that work for other conditions. First described by the neurologist Francis Xavier Dercum in the late nineteenth century, the disease remains poorly understood, and many people who have it wait years before receiving a correct diagnosis.
What Adiposis Dolorosa Looks and Feels Like
The hallmark of the disease is painful fat. That sounds deceptively simple, but the experience is anything but. The fatty deposits can take several forms: some people develop distinct lumps (lipomas) that are tender to the touch, while others have a more diffuse, widespread pain across large areas of subcutaneous fat without clearly defined masses. Researchers have proposed four subtypes based on how the fat is distributed: generalized diffuse (pain spread across broad areas of fatty tissue), generalized nodular (multiple painful lipomas scattered across the body), localized nodular (pain confined to specific fatty lumps), and juxta-articular (deposits clustered near joints, especially the knees).1PubMed Central. Dercum’s disease (adiposis dolorosa): a review of clinical presentation and management
The pain itself varies. Some people describe a deep, aching soreness that worsens with pressure or touch. Others experience sharp, burning sensations that can flare unpredictably. What makes the pain especially frustrating is that it can be present even in areas without visible lumps, and it does not always correlate with the size of any fatty deposit. On MRI and ultrasound, the lesions typically appear as small, oblong fatty nodules in the superficial layer of fat beneath the skin, mostly under two centimeters in diameter, with no imaging evidence of swelling or active inflammation.2PubMed. Adiposis dolorosa (Dercum’s disease): MRI and ultrasound appearances
Beyond pain, the disease carries a long list of associated symptoms. Easy bruising, fatigue, weakness, joint aches, bloating, constipation, shortness of breath, rapid heartbeat, and sleep disturbances all appear frequently. Cognitive complaints are common too: many people report difficulty concentrating, impaired memory, and a mental fog that compounds the physical burden.3PubMed Central. Review of Dercum’s disease and proposal of diagnostic criteria, diagnostic methods, classification and management
Who Develops It
Adiposis dolorosa most commonly shows up between the ages of 35 and 50. It overwhelmingly affects women, with estimates ranging from five to thirty times more common in women than in men.4PubMed Central. Dercum’s Disease: Bridging Present Understanding and Emerging Directions That sex ratio is striking even for conditions that skew female, and researchers have not fully explained why the gap is so large. Some speculate that hormonal factors play a role, particularly because the disease tends to emerge around or after menopause, but no single hormonal pathway has been convincingly linked to it.
The exact prevalence remains unknown. Part of the reason is that the disease is almost certainly underdiagnosed. Many patients are told they simply have obesity-related pain, fibromyalgia, or another chronic pain condition before eventually being identified. There is no blood test, no genetic marker, and no imaging feature that clinches the diagnosis on its own. It remains what clinicians call a “diagnosis of exclusion,” made by systematically ruling out other conditions and recognizing the pattern of painful adipose tissue in an overweight or obese person.5PubMed Central. Review of Dercum’s disease and proposal of diagnostic criteria, diagnostic methods, classification and management
What Is Actually Going Wrong in the Fat
This is where the science gets genuinely murky. Multiple theories have been proposed over the decades, and no single explanation has won out. The leading ideas center on inflammation, lymphatic dysfunction, and nervous system sensitization, and they may not be mutually exclusive.
Recent molecular work has found signs of adipose tissue dysfunction in affected patients, including immune cells infiltrating the fat and elevated levels of pro-inflammatory signaling molecules called adipokines. Those signals appear to fuel low-grade inflammation, interact with nearby nerves, and sensitize pain receptors.6PubMed Central. The Molecular Mechanisms Underlying Dercum’s Disease: Exploring the Intersection of Obesity, Pain, and Inflammation That would explain why the pain is disproportionate to the size of the fatty deposits: the issue is not the lump itself but the chemical environment surrounding it.
The inflammation story, however, has a complication. A case-control study comparing tissue biopsies from people with Dercum’s disease, obese controls, and normal-weight controls found that while inflammation was present in the fat of Dercum’s patients, it was not more pronounced than in the fat of healthy obese controls.7PubMed Central. Histology of adipose tissue inflammation in Dercum’s disease, obesity and normal weight controls: a case control study Obesity itself causes low-grade fat inflammation, so if Dercum’s patients have roughly the same amount, something else has to be making their fat painful. The inflammation may be a contributor rather than the root cause.
Another piece of the puzzle involves the lymphatic system. Imaging studies of Dercum’s patients have found that their lymphatic vessels are intact and dilated but move lymph sluggishly compared with controls.8PubMed Central. An abnormal lymphatic phenotype is associated with subcutaneous adipose tissue deposits in Dercum’s disease Sluggish lymph drainage could allow inflammatory mediators to linger in the tissue longer than they should, irritating nerves and contributing to pain. Some researchers have noted parallels with other conditions that involve lymphatic dilation, although the connection remains speculative.9IDCases. Infections preceding the development of Dercum disease
The honest summary is that the disease likely involves a combination of dysfunctional fat signaling, impaired lymphatic flow, and heightened nerve sensitivity, but nobody has nailed down how those factors interconnect or which one triggers the cascade. Genetic studies are thin, and there is no identified gene or clear inheritance pattern.
How Doctors Tell It Apart from Lipedema and Other Conditions
One of the biggest practical challenges with adiposis dolorosa is that it overlaps with several other conditions, and getting the right label matters because management differs. The two conditions most commonly confused with each other are Dercum’s disease and lipedema, a disorder in which fat accumulates symmetrically in the legs and arms, often with easy bruising and tenderness.
A study that directly compared the two groups found real differences. People with lipedema tended to have higher weight and more fat distributed around the hips and thighs, with a much higher rate of joint hypermobility. People with Dercum’s disease reported significantly higher pain scores on average, more abdominal pain, more shortness of breath, more migraines, and a higher rate of fibromyalgia and discrete lipomas. Lipedema patients, by contrast, bruised more easily. Fatigue and swelling were common to both.10PubMed. Differentiating lipedema and Dercum’s disease
Fibromyalgia itself is another frequent misdiagnosis or co-diagnosis. Both conditions involve widespread pain and fatigue, but fibromyalgia pain tends to localize at specific muscular tender points rather than in fatty tissue, and fibromyalgia does not involve lipomas. Still, some people carry both diagnoses simultaneously, and disentangling them is difficult.
Other conditions on the differential list include familial multiple lipomatosis (lipomas without significant pain), panniculitis (inflammation of the fat layer, but with distinct skin changes), and ordinary obesity-related musculoskeletal pain. The diagnosis of Dercum’s disease is clinical: a physician documents the combination of overweight or obesity, painful adipose tissue, and the absence of another explanation after a thorough workup.11PubMed Central. Dercum’s disease (adiposis dolorosa): a review of clinical presentation and management Imaging can support the picture but does not confirm it alone.
Mental Health and Quality of Life
The psychological toll of this condition deserves its own discussion because it is not merely a side effect of chronic pain. In a case-control study comparing Dercum’s patients with obese controls, over half of the Dercum’s group scored in the range for light or moderate depression, and one individual met criteria for severe depression. In the obese control group, the vast majority had no depression, and those who did scored in the light range only. The difference was statistically significant even after accounting for the fact that both groups were obese.12PubMed Central. Depression in Dercum’s disease and in obesity: a case control study
Depression and anxiety in Dercum’s disease likely stem from several compounding sources. Chronic pain itself is a well-known driver of depression. But patients also frequently describe the frustration of having a condition their doctors have never heard of, years of being told their pain is “just” from being overweight, and the social isolation that comes with a poorly understood illness. The cognitive symptoms, including memory problems and difficulty concentrating, add another layer. When your mind feels foggy on top of persistent pain, daily functioning erodes in ways that go well beyond what a pain scale captures.
Current Treatment Options
There is no cure for adiposis dolorosa, and treatment is focused on managing pain and improving function. Because the disease is rare and no large randomized controlled trials exist, most evidence comes from case reports, small case series, and a handful of modest studies. A systematic review of interventions found that the most commonly studied treatments were liposuction, dermolipectomy (surgical removal of fat and overlying skin), transcutaneous electrical stimulation, cyclic pneumatic compression, and various injections.13PubMed. Painful Adipose Tissue Disorder: A Systematic Review of Interventions for Dercum’s Disease
Liposuction is the intervention with the most published data. Studies have shown statistically significant drops in pain scores at three months and six months after surgery, with some patients maintaining improvement at three and five years, though the effect was not always significant at the one- and two-year marks.14PubMed. Painful Adipose Tissue Disorder: A Systematic Review of Interventions for Dercum’s Disease A separate study specifically assessing liposuction concluded that both subjective reports and objective pain measurements showed a significant decrease after surgery.15PubMed. Liposuction may reduce pain in Dercum’s disease (adiposis dolorosa) However, a quality-of-life study tempered those findings, noting that while there was a slight improvement after liposuction, the gain was not large enough on its own to clearly justify the procedure, and the causal link between the surgery and the improvement remained unclear.16PubMed. Quality-of-life in patients with Dercum’s disease–before and after liposuction In other words, liposuction helps some patients meaningfully, but it is not a reliable fix for everyone.
On the pharmacological side, no single drug has been established as a standard treatment. Lidocaine given intravenously has been reported to provide temporary pain relief. In one documented case, a patient with a 20-year history of the disease received complete pain relief after an intravenous lidocaine infusion, though the effect lasted only a few weeks before pain gradually returned.17PubMed. Long-standing pain relief of adiposis dolorosa (Dercum’s disease) after intravenous infusion of lidocaine Pregabalin, a nerve-pain medication also used for fibromyalgia, has been reported as helpful in individual cases, sometimes combined with manual lymphatic drainage to address the sluggish lymph flow.18PubMed. Dercum’s disease (Lipomatosis dolorosa): successful therapy with pregabalin and manual lymphatic drainage and a current overview Other agents that have appeared in case reports include methotrexate, corticosteroids, and interferon, but none has been tested in any rigorous way.
For many patients, the practical reality is a trial-and-error process through pain medications (nonsteroidal anti-inflammatory drugs, opioids, nerve-pain agents) alongside physical approaches like compression garments, lymphatic drainage therapy, and careful exercise. Weight loss through diet and exercise may help with the overall metabolic burden, but it does not reliably eliminate the painful deposits, and some patients report that their disease-specific pain persists even when they lose weight.
Emerging Therapies and Experimental Approaches
Research into new treatments has picked up over the past few years, and a few experimental approaches have generated early interest. Infliximab, a drug used in autoimmune conditions that targets a specific inflammatory protein (tumor necrosis factor alpha), has been reported to visually reduce lipoma size and improve subjective pain ratings. Deoxycholic acid, a bile acid that the body naturally produces and that has been developed as an injectable fat-reduction agent, has shown early promise: subcutaneous injection resulted in lower pain scores and smaller lipomas in reported cases.19PubMed Central. Dercum’s Disease: A Practical Review of Existing and Novel Therapies
Perhaps the most closely watched development is CBL-514, a small-molecule drug designed to trigger programmed cell death specifically in fat cells. It is currently in phase 2 clinical trials and has shown statistically significant reduction in lipoma size, earning Fast Track designation from the U.S. Food and Drug Administration, which is meant to speed development of drugs for serious conditions with unmet needs.20PubMed Central. Dercum’s Disease: A Practical Review of Existing and Novel Therapies Fast Track designation does not guarantee approval, but it signals regulatory recognition that the condition lacks adequate treatment. If CBL-514 proves effective, it would represent the first targeted therapy for the disease rather than a repurposed drug originally designed for something else.
None of these experimental treatments are yet standard of care. All of them have been studied in small numbers of patients, and larger trials are needed to establish whether the benefits hold up and what the side effects look like over time. Still, the pipeline is more active than at any point in the disease’s history, which is encouraging for a condition that has had essentially no dedicated drug development for over a century.
The Diagnostic Delay Problem
One of the most damaging aspects of adiposis dolorosa is how long it takes to get diagnosed. The exact prevalence of the disease has not been established, and most physicians encounter it rarely or never in their careers.21PubMed Central. Review of Dercum’s disease and proposal of diagnostic criteria, diagnostic methods, classification and management Because there is no definitive test and the condition’s main feature, painful fat in an overweight person, is easy to dismiss as ordinary obesity-related discomfort, many patients see multiple specialists over years before anyone considers Dercum’s disease.
The disease straddles several medical specialties without belonging squarely to any of them. Dermatologists, rheumatologists, endocrinologists, pain specialists, and surgeons may each see a piece of the picture. Francis Xavier Dercum himself was a neurologist, which gives a sense of how broad the overlap is.22PubMed Central. Francis Xavier Dercum: a man for all seasons Without a single “home” specialty, patients often bounce between providers, each of whom evaluates one symptom cluster and may miss the unifying diagnosis.
The weight factor makes this worse. Obese patients are routinely told that losing weight will solve their pain, and while weight management is reasonable general advice, it does not address the specific pathology in Dercum’s disease. The risk of diagnostic delay is compounded for patients whose clinicians attribute all of their symptoms to obesity without looking further. Proposed diagnostic criteria, namely the combination of generalized overweight or obesity with painful adipose tissue after exclusion of other causes, offer a practical framework, but only if clinicians think to apply it.
Living with a Condition Most Doctors Have Never Seen
For the people who have adiposis dolorosa, the rarity of the disease creates its own set of practical problems beyond the medical ones. Finding a knowledgeable provider can mean traveling long distances or relying on telehealth. Insurance coverage for treatments like liposuction, when they are performed for pain management rather than cosmetic reasons, is often denied initially and requires appeals. Support communities exist online but are small, and the research base is thin enough that even well-meaning physicians may have little to offer beyond general pain management protocols.
Patient advocacy has driven some of the recent research attention. The FDA’s Fast Track designation for CBL-514, for instance, reflects in part the advocacy work that has raised the visibility of the condition among regulators and researchers. As the molecular understanding of adipose tissue dysfunction grows across obesity research more broadly, Dercum’s disease stands to benefit from spillover knowledge, even if it does not attract large dedicated funding on its own. For now, though, the day-to-day reality for most patients remains one of managing an unpredictable, poorly understood disease with an improvised toolkit, waiting for the science to catch up.